Sign in to view content

Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases

Matthew Starr, MD

Video
Published 2022

Related

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2017
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more